Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
504.50    -0.50 (-0.10%)
Bid:
503.00
Ask:
504.50
Spread: 1.50 (0.298%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

27 Jul 2017 07:00

27 July 2017 – Tate & Lyle PLC

TRADING STATEMENT

This Trading Statement covers the period from 1 April 2017 to 30 June 2017, which is the first quarter of the financial year.

The Group made an encouraging start to the year with profit in constant currency ahead of the comparative period, and volume ahead in both divisions.

In core Speciality Food Ingredients:

North America, where the overall Food and Beverage market remained soft, saw modest volume growth with firmer volume from some larger customers, and also continued to make progress in broadening its customer base. Asia Pacific and Latin America, and Europe, Middle East and Africa delivered strong volume growth.

In the remainder of the Speciality Food Ingredients division, Food Systems volume was in line with the comparative period and SPLENDA® Sucralose performed as expected.

In Bulk Ingredients, the core business performed well driven by solid demand for sweeteners and industrial starches, firm US bulk sweetener margins, and continued strong manufacturing performance. In Commodities, performance was ahead of the comparative period.

Overall, we continue to expect that the Group will make underlying progress in the full year.

END

A conference call will be held today at 07.30am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call. Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666

Password: Tate & Lyle

A replay of this call will be available after the end of the live call for 14 days until 10 August 2017.

UK replay number: +44 (0) 20 8196 1998

Replay access PIN: 3389225#

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media Relations

Tel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz (FTI Consulting), Media Relations

Tel: +44 (0) 203 727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations at more than 30 facilities worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2017, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of Heartland Consumer Products LLC.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170726006037/en/

Copyright Business Wire 2017

Date   Source Headline
29th Apr 20253:30 pmRNSHolding(s) in Company
28th Apr 20255:15 pmRNSHolding(s) in Company
24th Apr 202512:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSIntegration update and pre-close statement
27th Mar 20257:00 amRNSDirectorate Change
14th Mar 202510:05 amRNSDirectorate declaration
11th Mar 20253:00 pmRNSHolding(s) in Company
5th Mar 202511:30 amRNSDirector/PDMR Shareholding
28th Feb 20254:30 pmRNSHolding(s) in Company
28th Feb 202510:15 amRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSAdditional Listing
20th Feb 20251:42 pmRNSDirector/PDMR Shareholding
13th Feb 20257:00 amRNSTrading Statement
4th Feb 20257:05 amRNSDirector Declaration
3rd Feb 20253:30 pmRNSTotal Voting Rights
23rd Jan 20255:30 pmRNSIssue of Debt
9th Jan 20255:54 pmRNSCompletion of Share Buyback Programme
9th Jan 20255:45 pmRNSTransaction in Own Shares
8th Jan 20255:17 pmRNSTransaction in Own Shares
8th Jan 20252:02 pmRNSDirector/PDMR Shareholding
7th Jan 20255:31 pmRNSTransaction in Own Shares
6th Jan 20256:10 pmRNSTransaction in Own Shares
6th Jan 20252:00 pmRNSDirectorate Change
3rd Jan 20255:28 pmRNSTransaction in Own Shares
2nd Jan 20255:20 pmRNSTransaction in Own Shares
2nd Jan 20252:10 pmRNSBlock listing Interim Review
2nd Jan 20252:00 pmRNSTotal Voting Rights
30th Dec 20245:36 pmRNSTransaction in Own Shares
27th Dec 20245:15 pmRNSTransaction in Own Shares
23rd Dec 20245:26 pmRNSTransaction in Own Shares
20th Dec 20245:31 pmRNSTransaction in Own Shares
19th Dec 20245:24 pmRNSTransaction in Own Shares
18th Dec 20245:37 pmRNSTransaction in Own Shares
17th Dec 20245:20 pmRNSTransaction in Own Shares
16th Dec 20245:37 pmRNSTransaction in Own Shares
13th Dec 20245:25 pmRNSTransaction in Own Shares
12th Dec 20245:34 pmRNSTransaction in Own Shares
12th Dec 20245:30 pmRNSDirector/PDMR Shareholding
11th Dec 20245:28 pmRNSTransaction in Own Shares
10th Dec 20245:32 pmRNSTransaction in Own Shares
9th Dec 20245:25 pmRNSTransaction in Own Shares
6th Dec 20245:33 pmRNSTransaction in Own Shares
5th Dec 20245:38 pmRNSTransaction in Own Shares
5th Dec 20242:30 pmRNSHolding(s) in Company
5th Dec 20242:00 pmRNSDirector/PDMR Shareholding
4th Dec 20245:32 pmRNSTransaction in Own Shares
4th Dec 20244:00 pmRNSHolding(s) in Company
3rd Dec 20245:21 pmRNSTransaction in Own Shares
3rd Dec 20243:00 pmRNSHolding(s) in Company
2nd Dec 20245:31 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.